Big Phar­ma’s woe­ful num­bers on drug R&D just got even worse

The an­a­lysts at De­loitte con­tin­ue to cal­cu­late a dwin­dling re­turn for Big Phar­ma’s R&D dol­lars. Their lat­est num­ber crunch­ing for the world’s top 12 bio­phar­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER